XmAb®104
Oncology (Combination)
Phase 1Active
Key Facts
About Xencor
Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.
View full company profile